effects. Meta-analysis of head-to-head comparisons represents a robust method for anticipating the benefit and risk of an emergent statin, such as rosuvastatin, in comparison to an extensively studied agent such as atorvastatin. METHODS: A systematic literature search to identify head to head clinical studies of R and A was conducted. Data were available for 30 comparisons of 1:1 dose ratios (R10mg vs. A10mg etc), 24 comparisons of 1:2 dose ratios (R5mg vs. A10mg etc) and six comparisons of 1:4 dose ratios (R5mg vs. A20mg etc). Treatment difference in benefit (% Low Density Lipoprotein-cholesterol [LDL-c] reduction) and risk (odds ratios for myalgia, serious adverse events and withdrawals due to adverse events, elevated Alaninaminotransferase [ALT] (3xULN), and Creatine Kinase [CK] (>10xULN), were estimated by meta-analysis (random effects) and presented in benefit risk planes. RESULTS: Analysis of 25 studies (~24,000 pts) demonstrated rosuvastatin to be significantly more efficacious than atorvastatin, for LDL-c reduction, at 1:1 and 1:2 dosage ratios. There were no significant differences between rosuvastatin and atorvastatin, at any dose ratio, for i) withdrawals due to adverse events, ii) myalgia, iii) serious adverse events, iv) death, v) ALT > 3x upper limit of normal (ULN), and vi) creatine kinase (CK) >10xULN. CONCLUSION: At 1:1 and 1:2 dose ratios, significant additional reductions in LDL-c are obtained by rosuvastatin at a comparable risk of the adverse events presented. To extend beyond the current approach of predicting warfarin benefit and harm independently in new atrial fibrillation (AF) patients by refining methods to identify predictors of the four combined benefit/harm outcome groups-i) no stroke/no bleed; ii) no stroke/bleed; iii) stroke/bleed; iv) no stroke/no bleed. METHODS: We analyzed patient-level data from the Atrial Fibrillation Investigators RCT database (n = 9155) and an observational database of AF patients managed by Kaiser Permanente Colorado (n = 5475). We classified patients based on the four benefit/harm outcome groups and applied decision tree modeling (CART) and polytomous logistic regression (PLR) to identify patient factors predicting each outcome group. Statistical significance was set at alpha = 0.05. RESULTS: CART and PLR consistently identified age and warfarin use as predictors for all outcome groups. Both techniques identified predictors of stroke/no bleed and no stroke/bleed not previously included in AF stroke and bleed risk-assessment tools that predict these outcomes independently (e.g., CHADS2 and HEMORR2HAGES). Methodology strengths and limitations were evident. CART provides a visual algorithm approach to risk. However, there is a lack of quantitative measurement (e.g., odds ratios [OR], confidence intervals) for predictors. While PLR results were thorough and predictor parameter estimates could be converted to ORs to indicate strength of association, the result of PLR is number-intensive. To calculate a patient's probability for each of the four outcome groups, the patient's data must be inputted into three separate equations. While both techniques can be used to calculate an individual patient's probability for each outcome group, PLR likely has more scope for application in a clinical setting. Once refined, a clinical prediction rule could be created based on identified predictors and their ORs.
PCV12 METHODS FOR INDIVIDUALIZING THE BENEFIT AND HARM OF WARFARIN
Kaiser Permanente Colorado, Aurora, CO, USA OBJECTIVE: To extend beyond the current approach of predicting warfarin benefit and harm independently in new atrial fibrillation (AF) patients by refining methods to identify predictors of the four combined benefit/harm outcome groups-i) no stroke/no bleed; ii) no stroke/bleed; iii) stroke/bleed; iv) no stroke/no bleed. METHODS: We analyzed patient-level data from the Atrial Fibrillation Investigators RCT database (n = 9155) and an observational database of AF patients managed by Kaiser Permanente Colorado (n = 5475). We classified patients based on the four benefit/harm outcome groups and applied decision tree modeling (CART) and polytomous logistic regression (PLR) to identify patient factors predicting each outcome group. Statistical significance was set at alpha = 0.05. RESULTS: CART and PLR consistently identified age and warfarin use as predictors for all outcome groups. Both techniques identified predictors of stroke/no bleed and no stroke/bleed not previously included in AF stroke and bleed risk-assessment tools that predict these outcomes independently (e.g., CHADS2 and HEMORR2HAGES). Methodology strengths and limitations were evident. CART provides a visual algorithm approach to risk. However, there is a lack of quantitative measurement (e.g., odds ratios [OR], confidence intervals) for predictors. While PLR results were thorough and predictor parameter estimates could be converted to ORs to indicate strength of association, the result of PLR is number-intensive. To calculate a patient's probability for each of the four outcome groups, the patient's data must be inputted into three separate equations. While both techniques can be used to calculate an individual patient's probability for each outcome group, PLR likely has more scope for application in a clinical setting. Once refined, a clinical prediction rule could be created based on identified predictors and their ORs.
CONCLUSION:
While methods under study need further refinement, these individual patient data analyses provide a useful step forward in the movement towards evidence-based individualization of drug therapy. Little is known about the frequency of recurrent angina following percutaneous and surgical procedures, the characteristics which put a patient at risk for recurrent angina and the timing of angina recurrence. METHODS: Patients enrolled in a large national managed care plan with a claim for a CABG, PCI or stent from January 1, 2003 to Decemeber 31, 2004 were selected if they were 35 or older, and enrolled one year prior and one year following their procedure. Patients were followed for one year after their index procedure for medication use, angina diagnosis by ICD-9 code and additional revascularization procedures. RESULTS: Following selection criteria 18,240 patients were eligible for analysis. The average age was 59 years, with 25% age 65 years and older. Most patients were male (78%). Of the 18,240 patients, 46% (8420) experienced angina (identified by angina diagnosis and/or two or more nitrate prescriptions) within a year following their index procedure. Of those patients experiencing angina, approximately a third (30%/2904) had another revascularization procedure following the angina diagnosis. The average time from initial procedure to second procedure, after angina diagnosis, was 73 days, although there is a wide range among patients (SD = 103 days). Risk factors for having angina following a revascularization procedure were younger age, female gender and having a PCI without a stent. CONCLUSION: Angina reoccurs in a considerable percentage of patients in the year following a percutaneous or surgical coronary procedure. A third of patients experiencing angina have a second procedure after experiencing recurrent angina. The onset of cardiovascular diseases, such as an acute myocardial infarction (AMI) shows certain circadian and seasonal variation. The development of vascular diseases may also be influenced by age and sex. The purpose of our study was to find out whether a weekly variation or a seasonal variation could be found in the occurrence of a heart attack in the group of women. METHODS: We have carried out a retrospective analysis among women with the diagnosis of AMI (n = 32,345) admitted to hospitals between 2000 and 2004 in Hungary, grouped in age groups below and above the age of 50. Data was collected from the data base of the National Health Insurance Fund Administration according to the International Classification of Diseases (ICD I21, I22). RESULTS: With consideration to seasonal variation, the peak period of AMI was during Spring, with the lowest number of events during Summer months. There was significant difference between numbers of events in each season (p < 0.01). The weekly peak period of AMI morbidity was found on the first day of the week, Monday; showing a gradually decreasing tendency until the last day of the week, Sunday (p < 0.01). No significant difference was found between the two age-groups regarding seasonal or weekly variation. CONCLUSION: In summary, the results of our study suggest that AMI incidence in women shows a characteristic variation regarding seasons and the days of the week, which should be taken into consideration in the development of prophylaxis strategies. Numerous studies have reported the weekly variation of an acute myocardial infarction. The Monday peek has been connected with higher rate of physical and mental, work-related stress. We wish to study the weekly variation of an acute heart attack in the group of workers and pensioners, and find out whether National Holidays on the first day of the week influence the weekly rhythm of a heart attack.
PCV14 EVALUATION OF RESISTANT HYPERTENSION IN A USUAL-CARE SETTING

PCV16 PERMANENT STRESS MAY BE THE TRIGGER OF A HEART ATTACK ON THE FIRST WORK-DAY OF THE WEEK
METHODS:
We have carried out the retrospective analysis of patients received at Hungarian hospitals with the diagnose of an acute heart attack (n = 88,687) between 2000 and 2005. Data were retrieved from the data-base of the National Health Insurance Fund in accordance with the International Classification of Diseases (ICD). RESULTS: According to the morbidity data of a heart attack, the weekly peek is on the first workday of the week, showing a gradually decreasing tendency until the end of the week. Morbidity rates on Mondays being National Holidays are similar to the number of events on Saturdays and Sundays (Z = -25,337; p < 0.001). There was a significant difference between number of events on work-days and weekends (Z = -26,638; p < 0.001). No marked difference has been found between workers under the age of 65 and pensioners above the age of 65, or between the two sexes. CONCLU-SION: The results of our study reveal that the occurrence of an AMI shows characteristic changes through the days of the week, and the first work-days of the week may be related with higher incidence of a heart attack. Such results urge finding the potential new methods of forecast and prevention. (IRD model) . Prior CHD patients Ն50 years (distribution based on NHANES data) with combined sub-optimal LDL-C (Ն100 mg/dL), HDL-C (Յ40 mg/dL, males; Յ50 mg/dL, females), and TG levels (Ն150 mg/dL) at baseline were modeled to predict CHD events and lipid goals attained over five years. IRD model covariates included age, gender, follow-up time, combined lipid goal achievement, and Deyo-Charlson co-morbidity index. CHD events included acute coronary syndrome, sudden coronary artery disease death, and cardiac catheterization (PCI). Patient therapy was based on a formulary with all major branded and generic lipid drugs. RESULTS: Using a hypothetical 1,000,000 member plan, 35,059 patients aged Ն50 years were identified with prior CHD. The percent of patients achieving LDL-C and TG goals over five years was higher in the IRD model versus FR model (68.9% vs. 62.7% and 69.9% vs. 49 .2%, respectively), while HDL-C goal achievement percent was comparable (53.4% vs. 54.5%). The number of patients experiencing a CHD event over five years was higher in the IRD versus FR model (17, 194 vs. 6387) , reflecting the inclusion of actual practice CHD intervention (i.e., PCI) in unstable angina (14,430 vs. 1461) . CONCLUSIONS: The established FR model appears to conservatively underestimate both lipid response and theoretical CHD events, nor does it account for CHD clinical intervention. The IRD model may better reflect the real world lipid response and CHD events, also accounting for actual event indicators of CHD intervention, being developed from a treatment population.
PCV17 PREDICTING CLINICAL OUTCOMES IN MIXED DYSLIPIDEMIA PATIENTS USING THE FRAMINGHAM RISK AND A NEW RISK EQUATION BASED ON A MANAGED CARE DATABASE
